All News

Mumps,Parotid

CRESS – A New Composite Measure for Primary Sjögren's Syndrome

d Jack Cush, MD

Randomized clinical trials in primary Sjögren's syndrome (pSS) are fraught with fault and inconclusive outcome measures, including the more recently developed EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI).  There's a new composite endpoint outcome for RCTs in pSS, called the Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS).

Read Article
kids,learn,book

Rheumatoid Arthritis Offspring Show Normal School Performance

d Jack Cush, MD

A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.

Read Article
FDA.approved.jpg

FDA Approves Anifrolumab in SLE

d Jack Cush, MD

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  

Read Article
ICYMI: FDA Approves IVIG in Dermatomyositis https://t.co/PoHtzDYekk The FDA has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/eAQa2oPOOf

Links:

Dr. John Cush RheumNow ( View Tweet)
Hands-Down Rheumatology - Sarcoidosis usually presents as a monarthritis or oligoarthritis. Late sarcoid arthritis affects knees, ankles, fingers (dactylitis). Bony lesions show honeycomb trabecular pattern). https://t.co/85zvhk4Poz https://t.co/pb9ABL5O8a

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Potential Birth Defects with Hydroxychloroquine HCQ is one of the safest meds used in rheumatology, but there is new claims data suggesting a small increase in the risk of malformations associated with first-trimester HCQ use. https://t.co/k1LOQvWlVm https://t.co/Ka96e733rp

Links:

Dr. John Cush RheumNow ( View Tweet)
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores. https://t.co/6Dfdnin1aI https://t.co/rJFn9WuCgO

Links:

Dr. John Cush RheumNow ( View Tweet)
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the FDA for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. https://t.co/22HVA32IAh https://t.co/xZNfepcDLQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Don't forget to register for the ACR Virtual Townhall Wednesday 8/4/21: 7 PM ET Re: COVID vaccination effectiveness for rheum patients w/real world data @ACRheum @alhkim @rheum_cat https://t.co/CKAwSLMv8R

Links:

k dao KDAO2011 ( View Tweet)

"Fibromyalgianess" is highlighted as a risk factor for undue, extended glucocorticoid use in rheumatoid arthritis (RA) patients, according to Wallace and colleagues in Rheumatology. https://t.co/uv19GSZsBV https://t.co/aSFlV9zeGt

Links:

Dr. John Cush RheumNow ( View Tweet)
Article in press: Can ANCA titers predict relapse in patients with GPA? Cohort study by @UofT_DoM - microscopic hematuria and MPO ab at month 12 predicted increased risk of relapse https://t.co/ks3Gj5iSLR

Links:

Seminars in Arthritis and Rheumatism seminarthrheum ( View Tweet)

Study from the UK BSRBR for #AS & 2043 pts showed 44% w/ at least 1 comorbidity. Each comorbidity was associated w/ 0.40 unit increase in BASDAI and 0.53 in spinal pain. More Dz activity w/ Depression, CHF and peptic ulcer, not CRP/ESR https://t.co/0vAnbjHicw

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Approves Anifrolumab in active, moderate-severe SLE on background standard of care therapies. https://t.co/22HVA32IAh https://t.co/NxJ4sWTWfE

Links:

Dr. John Cush RheumNow ( View Tweet)

Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs. https://t.co/Uu1VjAbKMi https://t.co/uGvTyLExjf

Links:

Dr. John Cush RheumNow ( View Tweet)
The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs). https://t.co/RNWrLR53Wx https://t.co/mMmKKrX9vx

Links:

Dr. John Cush RheumNow ( View Tweet)
Health personnel (HCP) @ long-term care facilities (LTCFs) are at high risk for COVID-19. March 2021, 57% of LTCF HCPs were vaccinated. COVID-19 vax was highest in MDs (75.1%); lowest nurses (56.7%) & aides (45.6%). https://t.co/VjHutcrh26 https://t.co/8aO1mFgC8f

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: The FDA has authorized baricitinib ALONE as treatment for COVID-19 hospitalized adults and pediatric patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) https://t.co/WMc78GmOLU https://t.co/Bp5tL4pRk5

Links:

Dr. John Cush RheumNow ( View Tweet)
Worth another share-- Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021 https://t.co/S0ownscRKv https://t.co/7QtynRKAd6

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: One of our top June videos WATCH: Is blindness with Tocilizumab in GCA a worry? Dr. David Liew ( @drdavidliew ) weighs in. #EULAR2021 https://t.co/eFrmbkW9Gy https://t.co/4tY3hEDj2j

Links:

Dr. John Cush RheumNow ( View Tweet)
Pain Persists in RA, Even Without Inflammation One-third of patients with rheumatoid arthritis had unacceptably high levels of pain 5 years after diagnosis, often despite low levels of inflammation, Swedish researchers found. https://t.co/K8zf1pE9jM https://t.co/aEBu7jVHft

Links:

Dr. John Cush RheumNow ( View Tweet)
×